Prof Suresh Senan speaks to ecancer about the patterns of disease progression with durvalumab after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).

The ADRIATIC trial investigates treatment options for small cell lung cancer patients post-chemo radiotherapy.

Patients receive either durvalumab or a placebo with durvalumab and tremelimumab.

Results show significant survival improvements for the durvalumab group, with fewer extrathoracic and brain relapses.

The findings support the use of prophylactic brain radiation, establishing durvalumab as the new standard of care for limited-stage small-cell lung cancer.